GlassScriptPhysician profile
Amaris Murray
NPI 1841844222
$6,671.03
in general payments reported to CMS, 2019-2025
30 companies · $1,276 in 2025
The $1,276 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,286 · 2022: $476 · 2023: $1,622 · 2024: $2,011 · 2025: $1,276.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,910.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,909.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $983.47 | 2021-2025 | |
| Biohaven Pharmaceuticals, INC. | $863.66 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $712.59 | 2022-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Astrazeneca Pharmaceuticals LP | $672.60 | 2023-2025 | Breztri, Farxiga, Airsupra |
| Neurocrine Biosciences, INC. | $510.86 | 2023-2025 | Ingrezza |
| Lundbeck LLC | $405.81 | 2022-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $369.90 | 2023-2025 | Caplyta |
| Viiv Healthcare Company | $305.23 | 2022-2023 | Dovato |
| Alkermes, INC. | $244.20 | 2023-2025 | Aristada, Lybalvi |
| Axsome Therapeutics, INC. | $233.04 | 2024-2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $191.05 | 2023 | Invega Trinza, Invega Sustenna |
| Indivior INC. | $186.14 | 2021-2025 | Sublocade |
| Vanda Pharmaceuticals INC. | $160.96 | 2024-2025 | Fanapt, Hetlioz |
| Glaxosmithkline, LLC. | $156.65 | 2021-2024 | Trelegy Ellipta |
| Dexcom, INC. | $117.75 | 2024 | Dexcom G7 Gss (161) |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $101.60 | 2024-2025 | Cobenfy |
| Orexo US, INC. | $64.98 | 2021 | |
| Phadia US INC. | $48.76 | 2022-2025 | Immunocap |
| Astellas Pharma US INC | $48.49 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $39.19 | 2022 | |
| Pfizer INC. | $38.13 | 2023 | |
| Lilly USA, LLC | $34.02 | 2024 | Mounjaro, Zepbound |
| Corium, LLC | $28.79 | 2025 | Azstarys |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $28.57 | 2024 | Abilify Maintena, Rexulti |
| Exact Sciences Corporation | $25.71 | 2025 | Cologuard Collection Kit |
| Collegium Pharmaceutical, INC. | $24.87 | 2021 | |
| Gilead Sciences, INC. | $22.60 | 2021 | |
| Allergan, INC. | $18.87 | 2021 | |
| Novo Nordisk INC | $17.54 | 2021 | |
| Idorsia Pharmaceuticals US INC | $15.00 | 2024 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amaris Murray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.